| __timestamp | Genmab A/S | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79529000 | 44820000 |
| Thursday, January 1, 2015 | 91224000 | 82080000 |
| Friday, January 1, 2016 | 102413000 | 97130000 |
| Sunday, January 1, 2017 | 146987000 | 121271000 |
| Monday, January 1, 2018 | 213695000 | 153548000 |
| Tuesday, January 1, 2019 | 342000000 | 202541000 |
| Wednesday, January 1, 2020 | 661000000 | 245164000 |
| Friday, January 1, 2021 | 1283000000 | 285773000 |
| Saturday, January 1, 2022 | 2676000000 | 325998000 |
| Sunday, January 1, 2023 | 3297000000 | 332540000 |
Unlocking the unknown
In the dynamic world of biotechnology, effective cost management is crucial for sustaining growth and innovation. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two prominent players: Genmab A/S and PTC Therapeutics, Inc., from 2014 to 2023. Over this period, Genmab A/S has seen a staggering increase in SG&A expenses, growing by over 4,000%, from approximately $80 million in 2014 to nearly $3.3 billion in 2023. This reflects their aggressive expansion and investment in operational capabilities. In contrast, PTC Therapeutics, Inc. has maintained a more modest growth trajectory, with expenses rising by about 640%, reaching $332 million in 2023. This comparison highlights the diverse strategies employed by biotech firms in managing operational costs, with Genmab A/S focusing on rapid scaling, while PTC Therapeutics, Inc. opts for steady growth.
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Genmab A/S or Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Breaking Down SG&A Expenses: Genmab A/S vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs PTC Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Amneal Pharmaceuticals, Inc. and PTC Therapeutics, Inc.
PTC Therapeutics, Inc. vs Merus N.V.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.